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Abstract
Background : The conventional dobutamine protocol for the investigation of induced myocardial
ischemia is well established. Our objective was to evaluate the effects of early administration of
atropine during the dobutamine stress echocardiogram, as compared to its conventional use.
Methods : One hundred and twenty-one patients were referred to the dobutamine stress
echocardiogram, for the investigation of myocardial ischemia and the administration of atropine
was randomized into three groups (A, B, C at 10, 20 and 40 mcg/kg/min of dobutamine,
respectively).
Results : The mean level of the double product was significantly lower in the group C patients
when compared to group B patients (p = 0.002). The mean test time (12.8 ± 3.1 and 18.7 ± 3.4 p=
0.0001) and the mean total dose of dobutamine (14 × 18 × 25 mg p = 0.008) were significantly
higher in group C patients than in group A & B patients. The mean test time was reduced in 6
minutes (31%) with the early administration of atropine in relation to the standard protocol. The
atropine dose used in the different groups was similar. Complications were uniform in all cases.
Conclusion : The early administration of atropine during the dobutamine-atropine stress
echocardiography significantly reduces duration of the test and the dose of amine without
increasing the number of complications, the total dose of atropine or the number of diagnostic
tests.
Background
Dobutamine-atropine stress echocardiography (DASE) is
well established in clinical practice, as it is considered to
be one of the main methods of imaging to determine the
presence of myocardial ischemia.
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Currently, the use of the 3 min. protocol has become the
most popular, beginning at 5 mcg/kg/min infusion of
dobutamine and reaching a maximum dose of 40 mcg/kg/
min, with the addition of atropine from the final stage on.
Even though atropine has been used more often at the end
of the stress test to increase heart rate and accuracy, this
agent is usually administered during or soon after the
maximum dose of dobutamine, with the patients receiv-
ing prolonged amine infusions which may increase side
effects. Besides, the test time is often extended.
Considering that a significant number of patients (32%)
do not reach a dobutamine stress echocardiographic end
point with the standard protocol [1], and the increasing
use of Beta blockers as anti-ischemic or anti-hypertensive
medication in the last decade, the following question
should be considered: Are the protocols employed in
stress echocardiography still in agreement with current
medical practice?
If the range of the ideal heart rate, which is of extreme
importance to the accuracy of the method, is compro-
mised, then the need for a more homogenous protocol
which counterbalances the employed therapeutic effect
becomes relevant so as to avoid damage to the diagnostic
and prognostic information of the test.
The aim of this study was to evaluate the effects of atro-
pine when initiated early during dobutamine stress
echocardiography in relation to its later usage.
Methods
One hundred and twenty-one consecutive patients exam-
ined were submitted to dobutamine stress echocardiogra-
phy. Treatment with anti-ischemic medication was not
interrupted before the test.
The patients were randomly divided into three protocols
of study (Figure 1): 1A) early administration of atropine
at a dose of 10 mcg/kg/min of dobutamine; B) early
administration of atropine at a dose of 20 mcg/kg/min of
dobutamine, and; C) late or standard administration of
atropine at a dose of 40 mcg/kg/min of dobutamine, in
case heart rate obtained was below 85% of maximum rate
expected for age (220 – age) and there was no criteria for
interruption of test (such as: new abnormality in wall
motion or a worsening of an existing one, heart rate = or
> 85% of maximum rate expected for age, important
increase of systolic or diastolic blood pressure (SBP > 220
mmHg and/or DBP > 110 mmHg), relevant cardiac
arrhythmia (supraventricular arrhythmia with high
response and/or malignant ventricular arrhythmia),
intense angina (specially if associated with worsening of
regional function), pronounced hypotension (decrease of
SBP > 20 mmHg) followed by symptomatology, and con-
clusion of protocol. Groups A & B were considered
belonging to the early dobutamine-atropine protocol
(Figure 1) and group C belonged to the late protocol (con-
ventional).
In group C, some patients did not require atropine during
the test (which is part of the standard protocol). The
patients of group C who did not receive atropine during
the test (n = 16) were not taken into account for pertinent
statistical analysis on the effects of atropine in the early or
late phase of the echocardiogram. For a better understand-
ing, we considered to be late protocol the patients of
group C who received atropine and standard protocol the
patients involved in group C who did or not require atro-
pine.
The current research was approved by the Ethical and
Research Committee of the hospital, and informal con-
sent was obtained from all the patients.
Stress echocardiogram
Two kinds of equipments were used in the study: a HDI
5000 (digitalization – "Image View") and a Sonos HP
5500, both with 4,0 MHz transducers.
The patients were submitted to the two-dimensional
echocardiograms and Doppler for full analysis of cardiac
performance. The images obtained were of the long axis,
short axis, apical four and two chambers which corre-
spond to the viewing of the myocardial segments supplied
by the main coronary arteries.
Dobutamine was diluted in a glucose solution and
administered through an infusion pump initially at a dose
of 5 mcg/kg/min and increased to 10, 20, 30 mcg/kg/min
every 3 minutes up to maximum dose of 40 mcg/kg/min
(according to each group). The atropine sulfate was initi-
Protocols A, B and C Figure 1
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ated at a dose of 0,25 up to 0,50 mg and increased in inter-
vals of 1 to 2 minutes respectively, until a maximum dose
of 2 mg. This agent was administered intravenously in the
last minute of the stage, whereas the dobutamine infusion
remained continuous.
During the exam, a three derivation electrocardiogram
(ECG) record was maintained, as well as a continuous
check up of heart rate and blood pressure before and after
the administration of atropine.
At the peak of test, after achieving the end points, the dob-
utamine and atropine infusions were interrupted and
monitoring was continued during 5 to 10 minutes of the
recovery phase (eventually, for a longer period if neces-
sary), until heart rate was lower than 100 bpm and other
clinical and hemodynamic parameters were normal.
Metoprolol was given intravenously (1 to 5 mg) during
recovery phase to revert the effects of the dobutamine-
atropine combination.
Echocardiographic evaluation
The left ventricle was divided into 16 segments [2]. Each
segment was described as: normal, hypokinetic, akinetic
or dyskinetic. A normal dobutamine stress echocardio-
gram was defined as having normal wall motion at rest
with an increase of its systolic thickening during stress
(hyperkinesia). The presence of ischemia (positive test)
was defined as the development of a new abnormality in
wall-motion or a worsening of an existing one during
stress (hypokinesia, akinesia or dyskinesia).
The echocardiograms were reviewed by two experienced
examiners ("off line"), who had no access to clinical and
angiographical data, and a consensus was reached when-
ever necessary.
Statistical analysis
The statistical methodology adopted for the comparison
of proportions between continuous variables was the X2
test or the Fisher exact Test, whenever the X2 test could not
be evaluated. For the comparison of means between the
two groups the t de Student test was applied for independ-
ent samples, or the Mann-Whitney test (non-parametric
test) whenever the variable did not present normal distri-
bution.
In situations where three groups had to be analyzed, the
comparison of means between the groups was made with
the Analysis of Variance (ANOVA). In this case, the Tukey
test of multiple comparisons was applied to identify
which groups differed from each other; this is an ANOVA
complementary test. The Analysis of Variance of Kruskal-
Wallis (non-parametric test) was used for the comparative
analysis of variables which did not present a normal dis-
tribution.
The adopted criteria for determining any significance was
the level of 5% (in other words, whenever the p value of
the statistical analysis was lower or equal to 0,05).
The analysis of all statistical tests was processed by the
SAS® system (Statistical Analysis System).
Results
Of the total sample (n = 121), 76 patients (63%) received
early atropine in two different groups (A & B), and 45
patients (37%) did or not receive atropine in the late pro-
tocol. On average 49% of the patients were taking Beta
blockers.
The demographic data of the three Groups are reported in
Table 1.
The hemodynamic response in the three Groups is sum-
marized in Figure 2 (blood pressure) and Figure 3 (heart
rate).
The dobutamine dose was lower for Groups A and B (Fig-
ure 4) and the test time was shorter for Groups A and B
(Figure 5).
The double product is higher in the Group B, as is showed
in Figure 6.
Results and complications of the three Groups are
described in detail in Table 2.
Discussion
The present study shows that the early administration of
atropine during dobutamine stress echocardiogram sig-
nificantly reduces test time and the dose of the sympatico-
mimetic amine without, however, increasing the number
of general or specific complications. Besides, the total
dose of atropine used was not higher when administered
early, but the double product presented a significant
increase with the addition of this agent when compared to
the isolated effect of dobutamine. In this way, the early
intervention with atropine resulted in a more balanced
test when related to chronotropism and inotropism, max-
imizing the double product, optimizing time and not
increasing side effects. This information is emphasized
when we consider the important sympathic-parasym-
pathic interaction in regulating the heart rate and ven-
tricular function[3].
Lessick et al [4] also confirmed our findings, showing a
reduction of test time with no increase of side effects
caused by the early administration of atropine.Cardiovascular Ultrasound 2006, 4:17 http://www.cardiovascularultrasound.com/content/4/1/17
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Regarding complications and test results (less number of
the sub-maximum tests), group B patients appeared to be
more adequate in relation to the other groups, but with-
out statistical significance.
In addition, no patients had any intoxication problem
with the higher doses of anti-muscarinic (2 mg), even
when administered to elderly patients.
Our findings confirm and expand previous studies sug-
gesting atropine is often required to achieve a maximum
The hemodynamic response (heart rate) in the three Groups Figure 3
The hemodynamic response (heart rate) in the three 
Groups.
Table 1: Demographic characteristics; risk factors; use of medication; and ECG, ECHO and CAT data, in each group.
Variables Group A (n = 41) Group B (n = 35) Group C (n = 29) p value
Age (± DP) 60,8 +/- 11 59,6 +/- 12 54 +/- 12 0,038
Weight 69,2 71,6 74 0,4
Gender, Male % 51,2 54,2 65 0,47
Test indications:
CAD investigation or pre-operative % 46 66 55 0,23
Evaluation of known CAD % 54 34 45 0,23
Previous history of MI % 40 26 32 0,43
History of angina % 58 68 41 0,089
History of heart failure % 39 21 24 0,17
Hypertension % 61 62 45 0,61
Diabetes Mellitus % 20 20 21 0,98
High cholesterol % 46 62 35 0,1
Family history for CAD % 49 60 46 0,49
Smoking % 29 31 24 0,8
Obesity % 36 28 45 0,4
Use of Beta blockers % 49 54 45 0,74
Use of calcium channel blockers % 12 20 10 0,48
Use of digitalic % 0 6 10 fp
Altered baseline ECG % 38 39 41 0,97
Altered baseline ECHO % 41 37 42 0,87
Normal ventricular function % 66 86 65 0,097
Previous CAT % 46 40 36 0,68
Previous PTCA % 19 12 10 0,6
Previous CABG % 17 17 10 0,69
CAD = coronary artery disease MI = myocardial infarction
PTca = percutaneous transluminal coronary angioplasty CABG = cardiac artery bypass grafting
ECG = eletrocardiogram with 12 derivations ECHO = echocardiogram CAT = cardiac catheterism fp = few patients (<10)
The hemodynamic response (systolic blood pressure) in the  three Groups Figure 2
The hemodynamic response (systolic blood pressure) in the 
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hemodynamic stress with dobutamine [5-8] and that ear-
lier administration of atropine does not seem to increase
the rate of serious adverse events [5,6,9,10].
Limitations
Diagnosis of the echocardiogram exams for the presence
of parietal disinergy was obtained by the qualitative and
subjective techniques, and not through quantitation
method of precision. However, visual evaluation of car-
diac motion remains not only the simplest method, but
also the most accurate for regional analysis [11].
We must also mention that the total testing time calcu-
lated only included the duration of the dobutamine infu-
sion and not recovery phase. The reasons that led to this
decision were the subjective nature of defining the end of
this phase, the custom of administering the antidote
(metoprolol) to almost every patient in order to reverse
the tachycardia induced by the method, and also due to
the fact that the patient may be transferred to another
room until all hemodynamic parameters are fully normal,
without necessarily using the examination room.
Conclusion
Based on our findings, we may conclude that:
The early intervention with atropine allowed for a more
balanced test regarding chronotropism and inotropism,
optimizing time and maximizing the double product,
besides being responsible for the reduction of the total
dobutamine dose without increasing side effects. In our
study, the early administration of atropine at 20 mcg of
dobutamine seemed the most adequate since it presented
a higher double product and fewer complications and
sub-maximum tests. Overall, the early administration of
atropine is indicated to all patients submitted to the test,
including those patients receiving Beta blockers.
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The double product in the Groups A, B and C Figure 6
The double product in the Groups A, B and C.
Dobutamine dose in Groups A, B and C Figure 4
Dobutamine dose in Groups A, B and C*
Test time Figure 5
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Table 2: Results and complications of the tests in the three groups.
Variables Groups p value
ABC
Results (%) :
Positive 24 17 14 0,44
Negative 54 71 62
Inconclusive (negative 
submaximum)
22 11 24
Complications (%) :
Hypertension 14 14 7 0,61
Supraventricular 
arrhythmia
10 8,5 3 fp
Ventricular arrhythmia 27 8,5 21 0,12
Hypotension 0 0 10 fp
Chest pain 7 8,5 14 0,7
O t h e r s  * 1 72 61 4 0 , 4 4
General Complications 58,5 54 55 0,92
fp = few patients (<5) * others = nausea, vomiting, tremor, headache